Follicular lymphoma is a common type of non-Hodgkin lymphoma (NHL) characterized by slow growth and primarily affects B lymphocytes in the lymphatic system. It is the most prevalent form of low-grade lymphoma, often asymptomatic in early stages, and …
Mantle cell lymphoma (MCL) is a rare subtype of non-Hodgkin lymphoma characterized by the uncontrolled growth of B lymphocytes in the mantle zone of lymph nodes. It often exhibits both indolent and aggressive traits, complicating diagnosis and …
Chemotherapy is a fundamental treatment for Hodgkin’s lymphoma, utilizing powerful drugs to kill or slow cancer cell growth. Administered in cycles via IV, oral, or intramuscular methods, it aims to maximize remission and minimize recurrence …
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma in the U.S., accounting for about one-third of cases, primarily affecting older adults, especially men in their mid-60s. It involves the rapid proliferation of …
Diffuse large B-cell lymphoma (DLBCL) is a fast-growing blood cancer affecting B-lymphocytes, accounting for about 25% of non-Hodgkin lymphoma cases in the U.S. Symptoms include swollen lymph nodes, fever, night sweats, and weight loss. Diagnosis …
Epkinly is a bispecific antibody targeting CD20 and CD3, representing a promising treatment for B-cell lymphomas, particularly diffuse large B-cell lymphoma (DLBCL). It enhances the immune system’s ability to identify and eliminate malignant …
Yescarta (axicabtagene ciloleucel) is an innovative CAR T-cell therapy designed to treat specific blood cancers, notably diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma. This treatment involves collecting a …
Epkinly (epcoritamab) is a groundbreaking treatment for diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin lymphoma, accounting for about 22% of new cases in the U.S. each year. This bispecific antibody targets CD3 on T …
Polivy (polatuzumab vedotin) is an innovative antibody-drug conjugate used in the treatment of diffuse large B-cell lymphoma (DLBCL), particularly for patients who have relapsed or are refractory to previous therapies. As the most common aggressive …
Yescarta is a revolutionary CAR T-cell therapy approved for treating adult patients with relapsed or refractory large B-cell lymphoma, particularly non-Hodgkin’s lymphoma (NHL). It works by utilizing genetically modified T cells to target and …
The article discusses Nodular Sclerosis Hodgkin’s Lymphoma (NSHL), highlighting its unique characteristic of Reed-Sternberg cells, which arise from B-lymphocytes. NSHL spreads predictably, starting in one lymph node group, allowing for …
Kymriah, the first FDA-approved CAR T-cell therapy, has significantly transformed cancer treatment, particularly for blood cancers like pediatric acute lymphoblastic leukemia (ALL) and adult diffuse large B-cell lymphoma (DLBCL). This innovative …
The article emphasizes the importance of close monitoring for patients receiving Kymriah, particularly during the initial weeks post-infusion when side effects like Cytokine Release Syndrome (CRS) and neurological toxicities are most likely. Regular …
Blincyto is a bispecific T-cell engager (BiTE) used to treat acute lymphoblastic leukemia (ALL) by targeting CD19 on B cells and CD3 on T cells, enhancing the immune system’s ability to eliminate cancer cells. The recommended dosage consists of …
Poteligeo (mogamulizumab) is a monoclonal antibody targeting CCR4, primarily used for treating relapsed or refractory mycosis fungoides (MF) and Sézary syndrome, types of cutaneous T-cell lymphoma (CTCL). It recruits immune effector cells to …
R-ICE (Rituximab, Ifosfamide, Carboplatin, and Etoposide) is a chemotherapy regimen primarily used for treating relapsed or refractory non-Hodgkin’s lymphoma and Hodgkin’s lymphoma. It combines an immunotherapy component (Rituximab) with …
The article discusses the side effects, dosage guidelines, financial considerations, and patient experiences related to Carvykti, a CAR-T cell therapy for relapsed or refractory multiple myeloma. Common side effects include cytokine release syndrome …
